Company Overview and News
Aspire Mining Ltd (ASX:AKM) has received strong pre-commitments for the minimum placement condition needed to complete a $15 million strategic financing package and will increase the placement to $2.1 million.
Aspire Mining Ltd (ASX:AKM) managing director David Paull speaks to Proactive Investors about the development company’s recent work and financing arrangements at its Ovoot Coking Coal Project in Mongolia.
Aspire Mining Ltd (ASX:AKM) is targeting early production of washed coal from the world-class Ovoot Coking Coal Project in northern Mongolia within 12 to 15 months of approval.
Aspire Mining Ltd’s (ASX:AKM) rail subsidiary Northern Railways LLC has been granted an 18-month extension to complete conditions relating to the Erdenet to Ovoot rail concession in northern Mongolia.
Aspire Mining Ltd (ASX:AKM) managing director David Paull speaks to Proactive Investors about the review of a rail feasibility study, carried out by wholly-owned rail subsidiary Northern Railways LLC, with the support of China Gezhouba International Ltd. This 547.7 kilometer railway extension will connect Aspire Mining’s large-scale Ovoot Coking Coal Project to the the town of Erdenet, and form part of the proposed Northern Rail Corridor extending across northern Mongolia into southern Russia.
Aspire Mining Ltd (ASX:AKM) has received results from pilot-scale carbonisation test work on a 300-kilogram bulk sample from its Nuurstei Coking Coal Project in Mongolia.
Aspire Mining Ltd (ASX:AKM) yesterday received a query from the ASX related to the company’s shares rising from 2.1 cents last Friday to 2.7 cents yesterday.
Aspire Mining Ltd (ASX:AKM) stands to gain from the growing support for the Erdenet to Ovoot Railway from both within Mongolia and the Tuva Republic in the Russian Federation.
Aspire Mining Ltd (ASX:AKM) managing director David Paull says "as a relatively small cap company, we've got our foot on a real giant, and realising the value in that giant is really what we're aiming to do through this year." The company’s plans for 2018 are focused on developing coking coal deposits in Mongolia to deliver international specification product to neighbouring international consumers.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...